Novartis receives EU approval for biosimilar Zessly Ankylosing Spondylitis (AS), Approvals, Biosimilars, Crohn's Disease, Dermatological Diseases, European Commission, FDA/Regulatory, Gastroenterological Diseases, Immunology, Oncology, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatological Diseases, Ulcerative Colitis Novartis’ Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Read more May 24, 2018/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2018-05-24 01:48:172018-05-24 11:08:25Novartis receives EU approval for biosimilar Zessly
